ClinicalTrials.gg
CompletedNCT06614491Updated Jan 8, 2026

SCOPE - Single-Point Classification Observational Peristomal Evaluation

An observational study in Ileostomy, Colostomy and Urostomy, sponsored by ConvaTec Inc.. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by ConvaTec Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
605
Ages
18 Years and older
Sex
All
01

Study summary

Study to create an ostomy dataset and collect stoma photos to enable evaluation of images digitally versus an in-person ostomy skin assessment.

Read the detailed description

The purpose of this study is to create an ostomy dataset and collect stoma photos to enable SACS 2.0 evaluation of images digitally versus an in-person ostomy skin assessment.

02

Conditions studied

  • Ileostomy
  • Colostomy
  • Urostomy
03

In context

Lead sponsor

ConvaTec Inc. is the lead sponsor of 46 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A total of 600 Subjects, or 200 Subjects with ileostomy, colostomy, or urostomy peristomal skin categories

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with ileostomy, colostomy or urostomy
  • Age ≥ 18 years of age
  • Able and willing to provide

Exclusion criteria

Exclusion Criteria:

  • Enterocutaneous fistulae
  • Patients with two or more ostomies
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
605 participants (actual)
Patient registry
No

Groups and cohorts

  • Ileostomy

    Subjects with ileostomy

  • Colostomy

    Subjects with colostomy

  • Urostomy

    Subjects with urostomy

06

What researchers measure

Primary outcomes

  1. Reliability of SACS assessment

    The equivalence of weighted Kappa concordance between SACS assessment via in-person skin assessment by an ostomy care nurse and SACS assessment via examining the skin via photo by a study nurse coordinator

    Time frame: Baseline

Secondary outcomes

  1. Ostomy dataset

    Frequency of peristomal skin health classification scores in 600 consecutive ostomates

    Time frame: Baseline

07

Study locations

4 sites
  • ConvaCare clinic
    São Paulo, Brazil
  • ConvaCare clinic
    Bogotá, Colombia
  • Convacare clinic
    Cali, Colombia
  • ConvaCare clinic
    Medellín, Colombia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Dec 2025, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2024
First posted
Sep 26, 2024
StartActual
Dec 6, 2024
Primary completionActual
Dec 31, 2025
CompletionActual
Dec 31, 2025
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06614491
Lead sponsor
ConvaTec Inc.
Responsible party
Sponsor
First posted
Sep 26, 2024
Start date
Dec 6, 2024
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
Jan 8, 2026

Study contacts

Sandra Guerrero, MD
principal investigator · Principal Investigator Colombia
Maria Angela Boccara de Paula, PhD
principal investigator · Principal Investigator Brazil

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion